Key result
Complete surgical excision remains the mainstay of therapy for soft tissue sarcomas, with adjuvant therapies offering modest benefits and targeted therapies showing promise for specific subtypes like GIST.
Complete surgical excision remains the primary curative treatment for soft tissue sarcomas, with adjuvant and targeted therapies playing a role in specific subtypes.
No takes yet. Share an insight, caveat, or question.
Supports surgery-first strategies in sarcomas; leaves open prospective trials of targeted agents beyond GIST.
Milgrom et al. (2018) conducted a review in Soft tissue sarcoma. Multimodal therapy (surgery, radiation, chemotherapy, targeted therapy) was evaluated. Complete surgical excision remains the mainstay of therapy for soft tissue sarcomas, with adjuvant therapies offering modest benefits and targeted therapies showing promise for specific subtypes like GIST.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: